Real needle-free GLP-1 exists: the Wegovy oral tablet (oral semaglutide 25 mg, FDA-approved December 2025, 13.6% weight loss in the OASIS 4 trial) and experimental microneedle patches from Daewoong Therapeutics (80% bioavailability in a 70-person Phase 1 study, 2028-2030 market estimate)
WADA's Prohibited List is updated every year
To test this, we propose a minimal feasible, biomarker-enriched, single-arm trial for this patient subset, with co-primary endpoints of safety and objective response rate (ORR)
Ann N Y Acad Sci 2004;1033:158-67
It is recommended to discuss with a healthcare aid to discuss the potential benefits and risks of Ozempic for weight loss, as well as to determine the right treatment plan based on your individual needs and past medical history
Part 1: short-term survival following a single laparotomy